MyDosage · Personal evidence dossier

Longevity & markers

Skin, cellular, and broad-system signals — preclinical to early human.

DSR-LONG-20260820

Issued August 20, 2026

Editorial · independent

01Top candidate

Thymosin α1

Thymic peptide (28-aa) · t½ ~2 h

Thymic-origin peptide marketed as Zadaxin in 30+ countries (not US) for chronic hepatitis B/C and as adjuvant.

Evidence Intelligence Score™

6.4/ 10Moderate

Strongest

Effects on the indexed outcomes are supported by randomized human data, with 1 citation on file.

Weakest

Effect sizes outside trial populations and durations beyond the studied window remain less characterized.

Unknowns

Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.

Outlook

Outlook: maturing. Expect the consensus to harden as multi-site replications publish.

02Ranked candidates

03Safety register